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ABSTRACT
Objective: To determine if women receiving intrauterine devices (IUCDs) outside of menses
have an acceptable rate of insertion problems and subsequent IUCD-related complications.
Design: Cross-sectional and prospective cohort study of insertions at times other than
during menses.
Setting: The study was carried out in two government family planning (FP) clinics in Nairobi,
Kenya.
Subjects: After appropriate pre-test and post-test HIV counselling, 1686 women requesting
IUCDs at two FP clinics between 1994 and 1995 in Nairobi were enrolled at baseline into a
study examining the effect of human immuno-deficiency virus (HIV) infection on IUCD-
related complications. Six hundred and forty nine women (156 HIV-infected and 493 HIV-
uninfected) were selected for the four month follow up study. They were classified according
to their menstrual cycle status at time of IUCD insertion.
Main outcome measures: Problems at the time of insertion (pain, bleeding, immediate
expulsion) and IUCD-related complications through four months.
Results: Rates of immediate insertion problems were low in the women who had insertions
during menses (7.0%), outside of menses (4.0%) or had oligomenorrhea/amenorrhea (2.6%).
The adjusted odds ratios for IUCD insertion problems outside of menses and in oligomenorrhea/
amenorrhea (versus women with insertion during menses) were 0.54 (95% CI 0.18 -1.59) and
0.39 (95% CI 0.12 -1.29) respectively. IUCD-related complications were higher in the
oligomenorrhea/amenorrhea (11.5%) or insertion outside of menses (6.9%), than the within
menses (4.3%) groups. However, the differences were not statistically significant. Adjusted
odds ratios for IUCD outside of menses and oligomenorrhoea/amenorrhea groups were 1.65
(95% CI 0.21 - 12.91) and 2.72 (95% CI 0.34 - 21.71) respectively.
Conclusion: The results confirm that the IUCD can be safely inserted outside of menses with
minimal insertion difficulties and subsequent complications. Availability of IUCDs outside
of menses may enhance IUCD acceptance in Kenya and create better opportunity for visual
screening of the cervix for sexually transmitted infections.
INTRODUCTION
Intrauterine devices (IUCD) are used by approximately
100 million women worldwide and are a highly effective,
safe, inexpensive and long-lasting contraceptive
method(1). The Copper (Cu) T 380A, one of the latest
generation copper IUCDs, provides safe and effective
contraception (99%) for 10 years and has a very low
expulsion rate(1,2).
Although their user effectiveness is higher than oral
contraceptives and implants, trends over a decade in family
planning use in Kenya show that, while IUCD showed only
a modest increase in uses, injections have experienced a
particularly steep increase (1-7%), pill use has tripled, and
female sterilisation doubled(3). Nevertheless, the relative
decline in IUCD use in Kenya has been attributed to five
interrelated factors; poor quality of care, fear of HIV
acquisition/transmission, poor product image, provider bias
or preference and shifting client preference(4).
IUCDs can be inserted safely at any time of the menstrual
cycle as long as pregnancy and other contra-indications are
ruled out(1,5). With the development of plastic devices in
the 1960s, insertion was frequently done during the menstrual
period, when the cervix may be more open. The availability
of resilient copper IUCDs provided further freedom in the
timing of fitting. Although some authors contend that a
relationship exists between timing of insertion and rates of
expulsion, pregnancy, and removals for pain/bleeding, this
relationship is weak and rigid adherence to insertion of an
IUCD during menses may be less important than the benefits
to be gained by insertion upon request(6). In Kenya, the
IUCD insertion for many years has been restricted to the
period during menses. This period is advantageous to the
providers since pregnancy can be ruled out unequivocally
and providers perceive that this timing enhances ease of
insertion and minimises menstrual disturbances.
Also bleeding problems can be masked if insertion is
done during menses. However, insistence on insertion
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during menses may result in a potential user either becoming
pregnant while waiting for the next menses or defaulting
in coming back to the clinic.
Use of a simple checklist to rule out pregnancy has
been recently tested and proved valid(7). This suggests
that IUCD insertion outside of menses can be done with
minimal risk of inserting into a pregnant uterus. Moreover,
in areas with high rate of sexually transmitted infections
(STIs), insertion during menses precludes the opportunity
to carefully examine the cervix and vagina for signs of
STIs to reduce dissemination of infections at the time of
the IUCD insertion. Other advantages of inserting an
IUCD outside of menses are easy and more accurate
assessment of cervical os combined with accurate uterine
sounding to reduce the chance of uterine perforation.
Visual assessment of the cervix can also help in screening
for malignancy especially if it is combined with the ability
for specimen collection such as the Pap smear.
This paper describes the experience of IUCD insertion
outside of menses in a large cohort of Kenyan women and
makes recommendations for IUCD service delivery
guidelines based on these findings.
MATERIALS AND METHODS
Study population and procedures: Details of study methods
have been described elsewhere(8). Briefly, a total of 1702 women
were referred to the study. Upon consultation with study staff, five
women chose not to have an IUCD inserted and 11 women were
examined but did not have an IUCD inserted for medical reasons
(including six women with mucopurulent cervical discharge, overt
cervicitis or abdominal tenderness). In all, 1686 women attending
two family planning clinics in Nairobi, between 1994-1995 requesting
an IUCD were recruited into the study. Because of the need to collect
cervical specimens for HIV DNA testing outside of menses,
menstruating women were asked to return not more than five days
after menses according to the last menstrual period (LMP). However,
some women returned while bleeding or spotting.
After written informed consent was obtained and HIV pre-
test counselling conducted, blood was drawn for HIV-l serological
testing. Study nurses conducted a brief interview to gather
demographic and recent sexual behaviour and contraceptive use
information. Physicians conducted a physical examination to
assess the condition of the vagina, cervix and any pelvic tenderness
and collected an endocervical swab for detection of HIV-1 DNA.
The IUCD was inserted if the woman met the local eligibility
criteria(9). Additional study eligibility criteria included: no use
of antibiotics within 14 days or long-acting penicillin within the
previous month; residing or working in Nairobi, having a sufficient
address for follow up and willing to return at one and four months
for follow up and agreeing to be tested for HIV infection.
Each physician completed a physical examination form by
noting the condition of the vaginal and cervical epithelia, colour
and quality and amount of vaginal and cervical discharge, any
pelvic, cervical motion or adnexal tenderness, and any problems
associated with IUCD insertion.
Process of IUCD insertion: In 1069 clients (63.4%) IUCDs
were inserted without the use of a tenaculum(10). This was done
at one site to minimise dangers of creating iatrogenic genital sores
or wounds which might enhance disease transmission, pain-
related anxiety and bleeding of the cervix. At the other clinic (n=
617; 36.6%) a tenaculum was used at all times. At both clinics
every effort was made to observe the highest standard of asepsis,
especially in the handling of the IUCD (Cu 380A) where no-touch
technique was used. Women were then scheduled for follow up at
one month but were advised to return earlier if a menstrual period
was overdue (>2 weeks), an infection was suspected or if they
experienced an adverse reaction to their IUCD.
Follow up component: All the 156 women who tested HIV-
1 positive and 493 randomly selected HIV-uninfected women
who presented within a week’s time at the same clinic as the
infected woman, were selected for the follow up.
At one month post-insertion, interviews and physical
examinations were again conducted and endocervical specimens
were collected for diagnosis of C. trachomatis and N. gonorrhoea.
At four months similar clinical and laboratory data collection
procedures were conducted except cervical specimens were
collected only from symptomatic women. Study physicians for
physical examination and specimen collection were masked to
participants’ HIV status throughout the study.
The laboratory methods have been described in detail
previously(8). HIV testing was conducted using two commercially
available ELISA kits(8). Women were tested for C. trachomatis
antigen using Syva Micro Track II EIA (Syva, Belgium).
Endocervical specimens for culture of N. gonorrhoea were taken
using sterile swabs and inoculated directly onto Thayer-Martin
Transport medium according to standard protocol and stored at 4°
C until used. After inoculation, plates were kept in CO
2
 jars at room
temperature until transported to the laboratory where they were
incubated for 48 hours at 37°C and read as positive or negative.
Comparison groups and outcome measures: Outcome
measures for this sub-study were problems at the time of insertion
(pain, bleeding, or immediate expulsion) and IUCD-associated
complications including: pelvic inflammatory disease (PID)
(11), full or partial IUCD expulsion, pregnancy, or IUCD removal
because of infection, pain, or bleeding.
Comparisons of insertion problems at baseline are made
among the entire group of 1,686 IUCD acceptors. Comparison of
short-term complications by menstrual history groups was limited
to the 615 women (144 HIV+, 471 HIV-) for whom longitudinal
information was available.
The participants were classified into one of three groups
according to their last menstrual period date. The groups were
women with blood on the swab and had their IUCD inserted
within eight days of LMP (3.4%) referred as “within Menses”
group; women not meeting this criterion but whose LMP was
less than 35 days before insertion were grouped as “outside
menses” (68.7%), while women whose last LMP occurred 35
days or more but less than six months, were referred to as
oligomenorrhoeic. The women whose menses had occurred
more than six months earlier were defined as “amenorrhoeic”.
The oligomenorrhoeic and amenorrhoeic groups were combined
to form a third group (27.9%). The high-risk period for pregnancy
was estimated to be between the 9th to 19th day of the cycle with
15.2% of women falling in this category while the last days in the
cycle (20-35 days) were considered as an infertile period (3.5%),
using the instructions for fertility awareness-based methods(1).
Statistical analysis: Baseline descriptive statistics were
provided for all women in the cross-sectional (n=1686) and
follow-up cohorts (n=615). Nineteen women could not be classified
because of missing menstrual data, thus leaving 1667 in the study
group. Logistic regression was used to estimate the odds ratios of
experiencing an insertion problem or IUCD-related complication
for women with IUCD insertions outsides of menses and those
experiencing oligomenorrhoea or amenorrhoea compared to
women with insertion during menses. We used adjusted odds
ratios derived from multivariate logistic models to estimate the
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risk ratio. We tested as co-founders: demographic, behavioural,
and physical assessment variables. We included co-founders in
multivariate models if covariate inclusion changed at least one
odds ratio for the groups by at least 10%. Models were tested for
goodness of fit with the Homer-Lemeshow statistic. SAS, version
6.12 (SAS Institute, Cary, NC, and USA), was used for all
analyses. The type I error rate was set at 0.05, two-tailed and
unadjusted for multiple comparison for all analyses.
RESULTS
Women among baseline (1686 women) and follow
up (615 women) cohorts shared similar characteristics.
Study participants were mainly parous (two or more live
births), living with a partner, aged over 20 years and had
at least secondary education (Table 1). Few participants
reported more than one sexual partner or use of condom in
the previous three months or a sexually transmitted
infections in the year before the baseline visit. About 36%
women had previously used IUCDs.
Table 1













Living with partner 88.2 86.3











STI in the last year 3.5 5.0
Partner with a possible STI in last year:
Yes 2.3 3.6




Coital frequency1 ≥ 3 times/week 45.7 45.9
Any condom use1 10.9 11.7
IUCD use
None 61.3 63.8
>3 months ago 24.4 23.0
≤3 months ago 14.3 13.2
Physical assessment data
Abnormal vaginal discharge 4.1 4.2





Cervical friability 18.4 19.7
Strawberry cervix 0.6 0.5
Cervical oedema 3.6 3.6
1Sexual/contraceptive behavior in 3 months prior to baseline interview
At baseline, about 4% of the participants had abnormal
vaginal discharge. Cervical friability (<20%), presence of
strawberry cervix (<1%) and cervical oedema (<4%) were
also minimal at baseline.
Proportions of women with insertion problems were
low in each of the three menstrual cycle groups including
4.0% in the outside of menses group, 7.0% in within menses
group and 2.6% in the oligomenorrhoea/amenorrhoea group
(Table 2). Pain was experienced more in the group who had
IUCDs inserted outside menses (2.1%), than in women
whose IUCDs were inserted during menses (0%). Immediate
expulsions occurred more among the within menses group
(7.0%) than in the outside menses (2.8%) and the
oligomenorrhoea/amenorrhoea group (1.7%). This
difference was statistically significant (p<0.05).
An IUCD was inserted in a woman who was later
found to be pregnant (0.06%). In this case, pregnancy was
not ruled out with a laboratory test at recruitment due to a
history of prolonged amenorrhoea for two years while
having Depo-Provera injections. Pregnancy was confirmed
at the one-month visit on examination and a positive
laboratory test.
Table 2
Insertion problems by menstrual cycle groups at insertion
(n = 1667)1,2
Characteristic (n = 1145) (n = 57) (n = 465)
Outside menses Within menses Oligomennorhoea/
amenorrhoea
No. % No. % No. %
Insertion problems
None 1099 96.0 53 93.0 453 97.4
Any3 46 4.0 4 7.0 12 2.6
Pain 24 2.1 0 0 6 1.3
Bleeding 18 1.6 1 1.8 5 1.1
IUCD immediately
expelled4 32 2.8 4 7.0 8 1.7
1 Nineteen women had missing menstrual information
2 One woman was excluded who received the IUCD while pregnant
3 Number of women with one or more insertion problems
4 p=0.05 for menstrual cycle groups comparison
Crude and adjusted odd ratios for insertion problems
according to menstrual grouping at insertion were not
statistically significant (Table 3). The adjusted odds ratios
for IUCD insertion outside of menses and for the
oligomenorrhoea/amenorrhoea group were 0.54 (95% CI
0.18 - 1.59) and 0.39 (95% CI 0.12 - 1.29) respectively,
after controlling for study site, age, education, edema,
recent IUCD use and coital frequency. HIV infection was
not associated with insertion problems and did not confound
the association between menstrual cycle groupings and
insertion problems.
We also evaluated whether use of a tenaculum during
IUCD insertion was associated with problems immediately
following insertion including pain, bleeding or expulsions.
There was no difference in either overall problems (3.2%
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with a tenaculum; 4.0% without a tenaculum; p=0.42) or
in perception of pain (1.8% of both groups, p=0.99)
among the two groups.
Table 3
Crude and adjusted odds ratios for insertion problems by menstrual
cycle groupings at insertion (n=1667)
Crude odds ratio Adjusted odds ratio
(95% CI) (95% CI)
Insertion problems
Within menses group 1.00 1.00
Outside menses group 0.56 (0.19 - 1.60) 0.54 (0.18 -1.59)1
Oligoamenorrhoea/
amenorrhoea 0.35 (0.11-1.13) 0.39 (0.12-1.29)1
1Adjusted for study site, age, education, edema, recent IUCD use and
coital frequency; Goodness of fit test: p=0.80
There were 49 IUCD-related complications including
three cases of PID, 21 expulsions and 24 removals. Failure
of method resulted in one pregnancy (Table 4). Proportions
of IUCD-related complications were lower in the outside
of menses (6.9%) and within menses groups (4.3%) than
oligomenorrhoea/amenorrhoea group (11.5%). However,
the differences were not statistically significant.
Table 4
IUCD-related complications outcome by menstrual cycle groupings
at insertion (N=605)1
Characteristic (n = 417) (n= 23) (n= 165)
Outside menses Within menses Oligomenorrhoea/
Amenorrhoea
No. % No. % No. %
IUCD-related complications
None 388 93.1 22 95.7 146 88.5
PID 1 0.2 0 0 2 1.2
Expulsion 10 2.4 1 4.3 10 6.1
Removal 18 4.3 0 0 6 3.6
Pregnancy 0 0 0 0 1 0.6
110 women had missing menstrual information
Table 5
Crude and adjusted odds ratios for IUCD-related complications by
menstrual cycle groupings at insertion (N=605)
Crude odds ratio Adjusted odds ratio
(95% CI) (95% CI)
IUCD-related complications
Within menses group 1.00 1.00
Outside menses group 1.64 (0.21 - 12.64) 1.65 (0.21 -12.91)1
Oligoamenorrhoea/
amenorrhoea 2.86 (0.36-22.47) 2.72 (0.34-21.71)1
1Adjusted for study site, education and used IUCD; Goodness of fit test:
P=0.5047
The adjusted odds ratios for IUCD insertion outside
of menses and in the oligomenorrhoea/amenorrhoea were
1.65 (95% CI 0.21 - 12.91) and 2.72 (95% CI 0.34 - 21.71)
respectively after controlling for study site, education, and
ever IUCD use (Table 5). HIV infection was not associated
with IUCD-related complications and did not confound
the association between menstrual cycle groupings and
complications.
DISCUSSION
These results confirm findings from other countries
that show that IUCD insertion is safe and effective at any
time of the menstrual cycle(12-13). An international study
of about 12,000 women who had IUCDs inserted at
different times during their menstrual cycles and similar
studies in the USA found no advantage over  the
conventional practice of insertion during the first five days
of the menstrual cycle(1). Thus for a woman who is
reasonably sure that she is not pregnant, the best time to
insert an IUCD is when she comes to a health center to
request it (6).
According to United States Agency for International
Development’s (USAID) Technical Guidance Working
Group, in the absence of a laboratory pregnancy test, a
provider can be reasonably sure a woman is not pregnant
if she has no symptoms or signs of pregnancy. These signs
include: no intercourse since last normal menses; correct
and consistent use of another reliable contraceptive method
within four weeks postpartum for non-lactating women;
within seven days post-abortion; fully breast-feeding,
amenorrhoeic and less than six months postpartum. These
criteria have been validated in Kenya where a study
showed an extremely low pregnancy rate of only 1%, in
women who came for family planning service outside of
menses (7).
The major advantage of inserting an IUCD outside of
menses, which has been illustrated in this study, is the
ability of the provider to visualise the cervix for abnormal
discharge and exclude the client if she has signs of STIs.
Severe cervical friability was seen in three patients, again
cautioning the provider to revisit the exclusion criteria for
these clients. Short-term complications (PID, expulsion,
removals and pregnancy) were low in this study. An IUCD
was inserted in one woman with amenorrhoea where
uncertainty of the ovulatory period is common.
Escape ovulation can unpredictably occur in this
group and care should be taken by providers either to
exclude pregnancy prior to insertion or ascertain coital
frequency and risk of pregnancy in the past months.
Insertion of IUCD in the window ovulatory period can
lead to unplanned pregnancies.
Immediate expulsion of the IUCDs occurred more in
the women who had their IUCDs inserted within menses
and the difference was statistically significant (p=0.05).
The expulsion rate during use was observed more in the
group with oligomenorrhoea/amenorrhoea. Reasons for
removals of IUCDs were due to pain, bleeding and infection
with only three cases of PID. The results show that this was
a low risk group for reproductive tract infections. The
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presence of blood on the swab signified in the majority of
cases menstrual flow, however, in a few cases there was
inter-menstrual bleeding. Visual inspection of the vagina
and cervix excluded six women judged to have had a
cervical infection. A presence of yellow/green discharge
in five clients underscores a need for either syndromic
management of STIs or where possible a laboratory back
up system for testing prior to insertion of IUCDs.
While previous studies suggest that IUCD insertion
outside of menses is feasible and safe, few studies have
reported on the practical experience of IUCD insertion
outside of menses in a large group of Kenyan women. The
results of this study indicate the feasibility and practicability
of insertion of IUCD outside of menses with minimal
complications. The results should motivate health providers
to offer IUCDs to women who are not menstruating. This
study also concludes that insertion of IUCD outside menses
avoids insertion in women with symptomatic cervical
infections and the turning away of clients who wish to
have an IUCD insertion and are at low risk of pregnancy.
The insertion of IUCD during menses misses those
women who have symptomatic STIs that cannot be detected
if the client came during menses. Motivational factors
such as having a pap smear specimen taken at the same
visit and creating an environment suitable for cervical
assessment are important health benefits of insertion outside
of menses.
The results confirm that the IUCD can be safely
inserted outside of menses in Kenya with minimal insertion
problems and subsequent IUCD-related complications.
Availability of IUCDs outside of menses would enhance
IUCD acceptance and create a better opportunity for
visual screening of the cervix for STI and malignancies
specifically carcinoma of the cervix.
We recommend that health providers in Kenya be
updated on the safety of insertion of IUCDs anytime
during the menstrual cycle, thus making family planning
services more accessible to women especially for those
women who come non-menstruating. Stanback et al(14)
have estimated that 35% of women who come for the first
time seeking family planning services are sent home due
to rigid menstrual requirements. More recently, Stanback
et al(7) have validated a simple checklist to rule out
pregnancy as a surrogate to an expensive pregnancy test
with high negative predictive value of 99%. Counselling
regarding IUCD insertion outside menses should also be
extended to paramedical staff and those involved in
community-based or outreach programmes so that the
community at large can be made aware of IUCD insertion
outside of menses.
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